Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Somatic to iPS Cell Reprogramming01:29

Somatic to iPS Cell Reprogramming

2.2K
Reprogramming alters the gene expression in somatic cells, transforming them into induced pluripotent stem (iPS) cells over several generations. Scientists can reprogram cells by introducing genes for four transcription factors—Oct4, Sox2, Klf4, and c-Myc (OSKM) by viral or non-viral methods. These factors are also known as Yamanaka factors after Shinya Yamanaka, who first generated iPS cells using mouse skin cells. Yamanaka was awarded the Nobel Prize in Physiology or Medicine in 2012...
2.2K
EPS and iPS Cells in Disease Research01:21

EPS and iPS Cells in Disease Research

2.7K
Embryonic and induced pluripotent stem cells are excellent models for disease research because of their ability to self-renew and differentiate into most cell types. Somatic cells from a patient are isolated and reprogrammed into induced pluripotent stem cells or iPSCs. These iPSCs are later differentiated into the desired cell type, which mirrors the diseased cell of the patient. In this way, disease models have been created for investigating diseases such as Down syndrome, type I diabetes,...
2.7K
Induced Pluripotent Stem Cells01:06

Induced Pluripotent Stem Cells

3.9K
Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic...
3.9K
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

170
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
170
iPS Cell Differentiation01:22

iPS Cell Differentiation

2.6K
The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.
2.6K
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

405
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
405

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Multi-Omics Data Reveal Estrogen-Driven Dysregulation and Stromal-Epithelial Signaling Alterations in Endometrial Polyps.

FASEB journal : official publication of the Federation of American Societies for Experimental Biology·2026
Same author

Single-cell sequencing uncovers disrupted stromal-macrophage communication as a driver of intrauterine adhesion progression.

Communications biology·2025
Same author

Modulation of the central nervous system immune response and neuroinflammation via Wnt signaling in health and neurodegenerative diseases.

Ibrain·2024
See all related articles

Related Experiment Video

Updated: May 21, 2025

Generation of Induced Neural Stem Cells from Peripheral Mononuclear Cells and Differentiation Toward Dopaminergic Neuron Precursors for Transplantation Studies
12:13

Generation of Induced Neural Stem Cells from Peripheral Mononuclear Cells and Differentiation Toward Dopaminergic Neuron Precursors for Transplantation Studies

Published on: July 11, 2019

7.1K

Somatic cell reprogramming for Parkinson's disease treatment.

Xiaozhuo Li1, Kevin Fang2, Fengping Wang3

  • 1School of Institute of Primate Translational Medicine Kunming University of Science and Technology Kunming China.

Ibrain
|March 19, 2025
PubMed
Summary

Cell reprogramming offers a novel therapeutic strategy for Parkinson's disease (PD) by generating dopamine neurons. This review explores its potential, methods, and limitations for PD treatment.

Keywords:
Parkinson's diseasecell reprogramminglineage reprogramming

More Related Videos

Selecting and Isolating Colonies of Human Induced Pluripotent Stem Cells Reprogrammed from Adult Fibroblasts
13:23

Selecting and Isolating Colonies of Human Induced Pluripotent Stem Cells Reprogrammed from Adult Fibroblasts

Published on: February 20, 2012

19.9K
Derivation of Adult Human Fibroblasts and their Direct Conversion into Expandable Neural Progenitor Cells
13:58

Derivation of Adult Human Fibroblasts and their Direct Conversion into Expandable Neural Progenitor Cells

Published on: July 29, 2015

15.4K

Related Experiment Videos

Last Updated: May 21, 2025

Generation of Induced Neural Stem Cells from Peripheral Mononuclear Cells and Differentiation Toward Dopaminergic Neuron Precursors for Transplantation Studies
12:13

Generation of Induced Neural Stem Cells from Peripheral Mononuclear Cells and Differentiation Toward Dopaminergic Neuron Precursors for Transplantation Studies

Published on: July 11, 2019

7.1K
Selecting and Isolating Colonies of Human Induced Pluripotent Stem Cells Reprogrammed from Adult Fibroblasts
13:23

Selecting and Isolating Colonies of Human Induced Pluripotent Stem Cells Reprogrammed from Adult Fibroblasts

Published on: February 20, 2012

19.9K
Derivation of Adult Human Fibroblasts and their Direct Conversion into Expandable Neural Progenitor Cells
13:58

Derivation of Adult Human Fibroblasts and their Direct Conversion into Expandable Neural Progenitor Cells

Published on: July 29, 2015

15.4K

Area of Science:

  • Neuroscience
  • Regenerative Medicine

Background:

  • Parkinson's disease (PD) involves dopamine neuron degeneration, leading to motor deficits and reduced quality of life.
  • Current treatments like L-DOPA and deep brain stimulation offer limited long-term benefits for PD progression.

Purpose of the Study:

  • To review cell reprogramming as a therapeutic strategy for Parkinson's disease.
  • To discuss the advantages, methodology, cell origins, efficiency, and limitations of cell reprogramming in PD treatment.

Main Methods:

  • Review of existing literature on cell reprogramming techniques for PD.
  • Analysis of cell origins, differentiation protocols, and in vivo/in vitro studies.
  • Evaluation of transformation efficiency and practical challenges.

Main Results:

  • Cell reprogramming shows promise for generating dopamine-producing cells for PD therapy.
  • Various cell sources and reprogramming methods are being investigated.
  • Challenges remain in achieving efficient and safe clinical application.

Conclusions:

  • Cell reprogramming represents a promising frontier in Parkinson's disease treatment.
  • Further research is needed to optimize efficiency, safety, and clinical translation.
  • Addressing practical application shortcomings is crucial for therapeutic success.